Jieqiong X. Liu

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 69 publications

Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study.

Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study.

Journal: Breast cancer research and treatment

Published: May 21, 2026

Fuzuloparib plus apatinib in BRCA-mutated breast cancer: balancing efficacy and accessibility in regional China - Authors' reply.

Fuzuloparib plus apatinib in BRCA-mutated breast cancer: balancing efficacy and accessibility in regional China - Authors' reply.

Journal: The Lancet. Oncology

Published: December 19, 2025

Clinical and Pathological Characteristics and Prognosis of Breast Cancer During Pregnancy and Postpartum: A Multicenter Retrospective Study.

Clinical and Pathological Characteristics and Prognosis of Breast Cancer During Pregnancy and Postpartum: A Multicenter Retrospective Study.

Journal: Cancer reports (Hoboken, N.J.)

Published: October 20, 2025

Longitudinal tissue analysis reveals microenvironmental changes correlate with combined immunotherapy and targeted therapy response in metastatic breast cancer.

Longitudinal tissue analysis reveals microenvironmental changes correlate with combined immunotherapy and targeted therapy response in metastatic breast cancer.

Journal: Journal for immunotherapy of cancer

Published: September 15, 2025

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: April 11, 2025

Shift work, thyroid function and liver function among subway workers.

Shift work, thyroid function and liver function among subway workers.

Journal: Occupational medicine (Oxford, England)

Published: January 17, 2025

Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial.

Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 26, 2024

A phase Ia study of a novel anti-HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors.

A phase Ia study of a novel anti-HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors.

Journal: Journal of translational medicine

Published: August 26, 2024

Narrative review on efficacy and safety of anti-angiogenesis in combination with immunotherapy in the treatment of breast cancer.

Narrative review on efficacy and safety of anti-angiogenesis in combination with immunotherapy in the treatment of breast cancer.

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer

Published: April 30, 2024

Effect of Multicomponent Intervention on Functional Decline in Chinese Older Adults: A Multicenter Randomized Clinical Trial.

Effect of Multicomponent Intervention on Functional Decline in Chinese Older Adults: A Multicenter Randomized Clinical Trial.

Journal: The journal of nutrition, health & aging

Published: November 24, 2023

Effect of 1 H-NMR serum lipoproteins on immunotherapy response in advanced triple-negative breast cancer patients.

Effect of 1 H-NMR serum lipoproteins on immunotherapy response in advanced triple-negative breast cancer patients.

Journal: Cancer science

Published: July 07, 2023

Radiomic and clinical data integration using machine learning predict the efficacy of anti-PD-1 antibodies-based combinational treatment in advanced breast cancer: a multicentered study.

Radiomic and clinical data integration using machine learning predict the efficacy of anti-PD-1 antibodies-based combinational treatment in advanced breast cancer: a multicentered study.

Journal: Journal for immunotherapy of cancer

Published: May 07, 2023

Showing 1-12 of 69

Last Updated: 09/26/2026